A comparison of the efficacy of Symbicort [budesonide/formoterol] single inhaler therapy (Symbicort Turbuhaler 160/4.5 mg 1 inhalation b.i.d. plus as-needed) and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults. A randomized, open, parallel-group, multicentre 26-weeks study
Phase of Trial: Phase IV
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Antiasthmatics; Budesonide/formoterol
- Indications Asthma
- Focus Therapeutic Use
- 21 Jan 2011 Trial phase changed from III to IV as reported by ClinicalTrials.gov.
- 07 Oct 2008 Results were reported at the Annual Congress of the European Respiratory Society.
- 07 Oct 2008 Primary endpoint 'Time to exacerbation of symptoms' has been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History